Here comes genomics, Take 2.
Pharmaceutical companies invested heavily in genetic studies in the frenzy after the sequencing of the human genome a decade ago, only to find it did not lead to the expected bonanza of new drugs.
Now, however, Regeneron Pharmaceuticals, a fast-growing biotechnology company, is undertaking an ambitious new genomics effort, in partnership with the Geisinger Health System, which treats three million people in Pennsylvania.
Regeneron will sequence DNA from about 100,000 volunteers among Geisinger’s patients, seeking genetic variants linked to different diseases that may provide clues to developing new drugs. Geisinger, in turn, hopes to use the genetic information to improve patient care.
Read the full, original story: Aiming to Push Genomics Forward in New Study
